The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

Abstract Background Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic effects, yet clinical data are scarcely available. Design and methods A p...

Full description

Bibliographic Details
Main Authors: Arwa Younis, Dana Eskenazi, Ronen Goldkorn, Jonathan Leor, Nili Naftali-Shani, Enrique Z. Fisman, Alexander Tenenbaum, Ilan Goldenberg, Robert Klempfner
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Cardiovascular Diabetology
Subjects:
Interleukin 1 beta
Vildagliptin
Dipeptidyl peptidase-4 inhibitors
Gliptins
Metformin
Online Access:http://link.springer.com/article/10.1186/s12933-017-0551-5

Internet

http://link.springer.com/article/10.1186/s12933-017-0551-5

Similar Items